S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NYSE:USNA

USANA Health Sciences (USNA) Stock Forecast, Price & News

$62.77
+0.87 (+1.41%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$61.72
$63.25
50-Day Range
$60.50
$67.90
52-Week Range
$48.61
$76.58
Volume
42,400 shs
Average Volume
70,562 shs
Market Capitalization
$1.21 billion
P/E Ratio
18.52
Dividend Yield
N/A
Price Target
$54.50

USANA Health Sciences MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
13.2% Downside
$54.50 Price Target
Short Interest
Healthy
3.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
1.05mentions of USANA Health Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.61 M Sold Last Quarter
Proj. Earnings Growth
14.75%
From $3.05 to $3.50 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

772nd out of 1,012 stocks

Medicinals & Botanicals Industry

8th out of 12 stocks


USNA stock logo

About USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
USANA Executive Director honored at Utah event
USANA Releases 2022 Sustainability Report
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Q1 2023 USANA Health Sciences Inc Earnings Call
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Company Calendar

Last Earnings
2/07/2023
Today
5/29/2023
Next Earnings (Estimated)
7/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.50
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
-13.2%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$69.35 million
Pretax Margin
10.66%

Debt

Sales & Book Value

Annual Sales
$998.60 million
Cash Flow
$4.73 per share
Book Value
$23.60 per share

Miscellaneous

Free Float
19,234,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Kevin G. Guest
    Chairman & Chief Executive Officer
  • Jim BrownJim Brown
    President
  • Walter NootWalter Noot
    Chief Operating Officer
  • G. Douglas Hekking
    Chief Financial Officer
  • Robert Andrew SinnottRobert Andrew Sinnott
    Chief Scientific Officer













USNA Stock - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price forecast for 2023?

2 brokerages have issued 1-year price targets for USANA Health Sciences' stock. Their USNA share price forecasts range from $53.00 to $56.00. On average, they expect the company's stock price to reach $54.50 in the next twelve months. This suggests that the stock has a possible downside of 13.2%.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2023?

USANA Health Sciences' stock was trading at $53.20 at the beginning of the year. Since then, USNA shares have increased by 18.0% and is now trading at $62.77.
View the best growth stocks for 2023 here
.

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 406,700 shares, an increase of 16.2% from the April 15th total of 350,000 shares. Based on an average daily volume of 78,700 shares, the short-interest ratio is presently 5.2 days. Currently, 3.6% of the company's shares are sold short.
View USANA Health Sciences' Short Interest
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) posted its earnings results on Tuesday, February, 7th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.35 by $0.31. The firm had revenue of $227.96 million for the quarter. USANA Health Sciences had a trailing twelve-month return on equity of 15.31% and a net margin of 6.70%. During the same quarter in the previous year, the company posted $1.03 earnings per share.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $2.40-$3.30 for the period, compared to the consensus estimate of $2.85. The company issued revenue guidance of $875.00 million-$950.00 million, compared to the consensus revenue estimate of $935.33 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.04%), Renaissance Technologies LLC (6.28%), Pzena Investment Management LLC (4.24%), Dimensional Fund Advisors LP (3.11%), State Street Corp (2.22%) and Acadian Asset Management LLC (1.38%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $62.77.

How much money does USANA Health Sciences make?

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.21 billion and generates $998.60 million in revenue each year. The company earns $69.35 million in net income (profit) each year or $3.39 on an earnings per share basis.

How many employees does USANA Health Sciences have?

The company employs 1,900 workers across the globe.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.

This page (NYSE:USNA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -